Related Experiment Video
Updated: Apr 12, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
19.5K
Cognitive enhancing agents in schizophrenia and bipolar disorder
Annabel Vreeker1, Annet H van Bergen1, René S Kahn1
1University Medical Center Utrecht, Department of Psychiatry, Brain Center Rudolf Magnus, The Netherlands.
Summary
Cognitive deficits are common in schizophrenia and bipolar disorder (BD). Current treatments are limited, with few agents studied for BD and none convincingly proven for schizophrenia, highlighting the need for new research directions.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Cognitive dysfunction is a core symptom in schizophrenia and bipolar disorder (BD).
- Schizophrenia shows cognitive decline preceding psychosis, while BD involves cognitive decline post-symptom onset, with high intelligence being a risk factor.
- Research on cognitive-enhancing agents is extensive for schizophrenia but scarce for BD.
Purpose of the Study:
- To review pharmacological agents targeting cognitive deficits in schizophrenia and bipolar disorder (BD).
- To examine agents affecting dopaminergic, cholinergic, and glutamatergic pathways in schizophrenia.
- To assess the cognitive effects of lithium, anticonvulsants, and antipsychotics in BD.
Main Methods:
- Literature review of pharmacological interventions for cognitive dysfunction in schizophrenia and BD.
- Analysis of studies focusing on neurotransmitter pathways (dopaminergic, cholinergic, glutamatergic) in schizophrenia.
- Review of cognitive effects of mood stabilizers and antipsychotics in BD.
Main Results:
- No cognitive-enhancing agents have been convincingly developed for schizophrenia.
- Cognitive effects of pharmacological agents in BD remain understudied.
- Current research has not yielded effective treatments for cognitive deficits in either disorder.
Conclusions:
- Effective cognitive-enhancing agents for schizophrenia and BD are lacking.
- Future research should target early stages of schizophrenia (prodromal, ultra-high risk) and later stages of BD for effective treatment.
- Novel therapeutic strategies are needed to address incapacitating cognitive deficits in these conditions.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
896
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
896
01:24Mania and Antimanic Drugs: Overview
790
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
790
01:26Psychosis: Goals of Pharmacotherapy
676
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
676
01:28Psychosis and Antipsychotic Drugs: Overview
1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
01:23Antidepressant Drugs: MAOIs and Other Agents
1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
1.4K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.4K